DAX24.740 -0,6%Est506.215 -0,3%MSCI World4.343 -0,1%Top 10 Crypto7,6500 -3,9%Nas25.477 -0,4%Bitcoin53.478 -2,9%Euro1,1359 -0,2%Öl73,23 -4,9%Gold4.001 -2,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 SpaceX A42D4F Micron Technology 869020 Infineon 623100 NVIDIA 918422 SAP 716460 Lufthansa 823212 Volkswagen (VW) vz. 766403 Siemens Energy ENER6Y TKMS thyssenkrupp Marine Systems TKMS00 Deutsche Telekom 555750 RENK RENK73 Microsoft 870747 Novo Nordisk A3EU6F Bayer BAY001
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Rheinmetall-Crash belastet: DAX schließt in Rot -- US-Börsen uneinheitlich -- KNDS-Börsengang fix -- Samsung: Milliarden-Rückkauf -- SK hynix, TUI, KI-Titel, Cerebras, Palantir, Arm, Intel im Fokus
Top News
Öl: Jetzt ist ein hohes Überangebot denkbar Öl: Jetzt ist ein hohes Überangebot denkbar
Coinbase-CEO: Bitcoin-Boden bei 60.000 US-Dollar wahrscheinlich erreicht Coinbase-CEO: Bitcoin-Boden bei 60.000 US-Dollar wahrscheinlich erreicht
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Scinai Immunotherapeutics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
0,2480 EUR ±0,0000 EUR ±0,00 %
BMN
0,2760 USD -0,0069 USD -2,44 %
BTT
finanzen.net zero
Scinai Immunotherapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone
Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA40DEH

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS09073Q3039

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolSCNI

Scinai Immunotherapeutics Aktien News

DatumMeistgelesen
finanzen.netScinai Immunotherapeutics präsentierte Quartalsergebnisse
BenzingaWhy Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today
PR NewswireScinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL
Wer­bungScinai Immunotherapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
finanzen.netScinai Immunotherapeutics: So schnitt der Konzern im vergangenen Quartal ab
PR NewswireScinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances
PR NewswireScinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities
finanzen.netScinai Immunotherapeutics hat Bilanz für das abgelaufene Quartal gezogen
PR NewswireScinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet
PR NewswireScinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN
PR NewswireScinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"
PR NewswireScinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025
PR NewswireScinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.
finanzen.netScinai Immunotherapeutics gab Ergebnis zum abgelaufenen Quartal bekannt
PR NewswireScinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn
finanzen.netScinai Immunotherapeutics stellte Zahlen zum jüngsten Quartal vor
PR NewswireScinai Announces Annual Financial Results for 2024
PR NewswireScinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases
PR NewswireScinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions
PR NewswireScinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025
PR NewswireSCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT
PR NewswireScinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences
PR NewswireScinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.
PR NewswireProf. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board
PR NewswireDr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board
finanzen.netScinai Immunotherapeutics gewährte Anlegern Blick in die Bücher
PR NewswireScinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million
PR NewswireScinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024
PR NewswireScinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies
PR NewswireScinai Regains Full Compliance with Nasdaq Listing Requirements
PR NewswireScinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000
PR NewswireScinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder
PR NewswireScinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23
PR NewswireScinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity
PR NewswireScinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb
PR NewswireScinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model
PR NewswireScinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity
PR NewswireScinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
finanzen.netScinai Immunotherapeutics: Zahlen zum abgelaufenen Jahresviertel
PR NewswireScinai Publishes Q1 2024 Financial Results and Provides Business Update
PR NewswireScinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

Scinai Immunotherapeutics News

Scinai Immunotherapeutics News: auf dieser Seite finden Sie alle Scinai Immunotherapeutics News und Nachrichten zur Scinai Immunotherapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Scinai Immunotherapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Scinai Immunotherapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.